Tinengotinib

• CAT Number: I045092
• CAS Number: 2230490-29-4
• Molecular Formula: C20H19ClN6O
• Molecular Weight: 394.86
• Purity: ≥95%
• Synonyms: 4-[9-(2-chlorophenyl)-6-methyl-2,4,5,8,12-pentazatricyclo[8.4.0.03,7]tetradeca-1(14),3,6,8,10,12-hexaen-13-yl]morpholine
• InChI: InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26)
• InChIKey: DQFCVOOFMXEPOC-UHFFFAOYSA-N
• SMILES: CC1=C2C(=NN1)NC3=CC(=NC=C3C(=N2)C4=CC=CC=C4Cl)N5CCOCC5

Tinengotinib（Cat No.:I045092）is a clinical-stage, multi-kinase inhibitor targeting key oncogenic drivers such as FGFR, VEGFR, Aurora B, and CSF1R. Designed for broad-spectrum anti-tumor activity, it disrupts tumor proliferation, angiogenesis, and immune evasion. Tinengotinib is being investigated for use in solid tumors, including non-small cell lung cancer and gastrointestinal malignancies, particularly in patients with kinase-driven mutations or resistance to single-target therapies. Its multi-targeted mechanism enhances therapeutic efficacy while potentially reducing resistance. Tinengotinib is supplied for research focused on kinase signaling, tumor microenvironment modulation, and next-generation cancer therapeutics.